- Home
- BIIB vs DT Comparison
BIIB vs DT Comparison
Compare BIIB & DT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- DT
- Stock Information
- Founded
- BIIB 1978
- DT 2005
- Country
- BIIB United States
- DT United States
- Employees
- BIIB N/A
- DT N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- DT Computer Software: Prepackaged Software
- Sector
- BIIB Health Care
- DT Technology
- Exchange
- BIIB Nasdaq
- DT Nasdaq
- Market Cap
- BIIB 18.8B
- DT 16.3B
- IPO Year
- BIIB 1991
- DT 2019
- Fundamental
- Price
- BIIB $125.00
- DT $55.01
- Analyst Decision
- BIIB Buy
- DT Buy
- Analyst Count
- BIIB 27
- DT 26
- Target Price
- BIIB $188.17
- DT $60.71
- AVG Volume (30 Days)
- BIIB 1.3M
- DT 2.7M
- Earning Date
- BIIB 07-31-2025
- DT 08-06-2025
- Dividend Yield
- BIIB N/A
- DT N/A
- EPS Growth
- BIIB 26.39
- DT 205.77
- EPS
- BIIB 10.12
- DT 1.59
- Revenue
- BIIB $9,816,400,000.00
- DT $1,698,683,000.00
- Revenue This Year
- BIIB N/A
- DT $18.86
- Revenue Next Year
- BIIB N/A
- DT $14.61
- P/E Ratio
- BIIB $12.41
- DT $34.69
- Revenue Growth
- BIIB 1.59
- DT 18.75
- 52 Week Low
- BIIB $110.04
- DT $39.30
- 52 Week High
- BIIB $238.00
- DT $63.00
- Technical
- Relative Strength Index (RSI)
- BIIB 45.14
- DT 56.61
- Support Level
- BIIB $123.21
- DT $54.11
- Resistance Level
- BIIB $129.27
- DT $56.17
- Average True Range (ATR)
- BIIB 3.00
- DT 1.25
- MACD
- BIIB -0.77
- DT -0.17
- Stochastic Oscillator
- BIIB 21.06
- DT 53.19
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About DT Dynatrace Inc.
Dynatrace is a cloud-native company that focuses on analyzing machine data. Its product portfolio, delivered as software as a service, allows a client to monitor and analyze its entire IT infrastructure. Dynatrace's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to use it for a variety of applications throughout their businesses.